Feline immunodeficiency virus (FIV)

The feline immunodeficiency virus (FIV) vaccine was developed to protect cats against a retrovirus that causes progressive immune system dysfunction similar to human immunodeficiency virus (HIV) in people. FIV belongs to the lentivirus genus of retroviruses and establishes lifelong infection in cats, gradually compromising immune function over months to years and eventually predisposing affected cats to opportunistic infections and certain cancers. The FIV vaccine represented a significant achievement in veterinary medicine as one of the first vaccines developed against a lentivirus, and its development provided insights relevant to HIV vaccine research. Classified as a non-core vaccine, FIV vaccination is recommended only for cats at elevated risk of exposure rather than as a universal recommendation.

The FIV vaccine contains inactivated (killed) virus particles from two FIV subtypes (clades A and D) combined with an adjuvant to enhance immune response. The dual-subtype formulation was designed to provide broader protection against the genetic diversity of FIV strains circulating in cat populations. When administered according to the recommended protocol, the vaccine stimulates production of antibodies against FIV, which can be detected through standard FIV serological testing. This antibody response is both the mechanism of protection and a significant consideration for vaccination decisions, as vaccinated cats will test positive on antibody-based FIV tests regardless of actual infection status, complicating future testing and potentially affecting the cat's medical and adoption prospects.

Feline immunodeficiency virus spreads primarily through bite wounds, making aggressive cats and those who engage in fighting behavior most likely to transmit and acquire infection. Free-roaming intact male cats face the highest risk due to territorial fighting behavior, while indoor cats with no exposure to potentially infected cats face minimal risk. The virus does not spread efficiently through casual contact such as sharing food bowls or mutual grooming, unlike the related feline leukemia virus (FeLV). Understanding FIV transmission patterns is essential for identifying appropriate vaccination candidates, as the vaccine provides benefit only to cats with genuine exposure risk. Cats who live exclusively indoors with other FIV-negative cats have negligible exposure risk and do not require vaccination.

The decision to vaccinate cats against FIV requires careful consideration of exposure risk, the implications of vaccine-induced antibodies for future testing, and the individual circumstances of each cat. The vaccine's availability has varied over time in different markets, and its use has been controversial within the veterinary community due to concerns about test interference and questions about protective efficacy against diverse FIV strains. Veterinary guidance is essential for navigating these complex considerations and determining whether FIV vaccination is appropriate for individual cats. When vaccination is pursued, cat owners must understand the testing implications and maintain permanent documentation of vaccination status to prevent future misidentification of vaccinated cats as FIV-infected.

The primary indication for FIV vaccination is prevention of feline immunodeficiency virus infection in cats at elevated risk of exposure through bite wounds from infected cats. FIV causes a chronic infection that progressively damages the immune system, eventually leading to acquired immunodeficiency syndrome in cats (sometimes called feline AIDS). Infected cats may live for years with minimal symptoms before developing clinical disease, but once immunodeficiency develops, they become susceptible to various secondary infections, certain cancers, and neurological problems. There is no cure for FIV infection, making prevention through avoiding exposure or vaccination the only options for protecting cats from this serious disease.

Outdoor cats who may encounter unfamiliar cats represent the primary target population for FIV vaccination consideration. Cats who go outdoors, particularly those who roam freely in areas where other cats are present, face potential exposure to FIV through aggressive interactions with infected cats. Intact male cats face the highest risk due to their territorial behavior and tendency to fight, but any cat who goes outdoors and might encounter unknown cats has some exposure risk. The decision to vaccinate should consider the specific circumstances, including the cat's temperament, the local cat population density, and whether encounters with unfamiliar cats are likely. Truly supervised outdoor access with no opportunity for cat-to-cat contact presents minimal FIV risk.

Cats in multi-cat households that include FIV-positive cats historically represented another indication for vaccination. When FIV-positive cats were discovered in households, vaccination of negative housemates was sometimes recommended to reduce transmission risk. However, current understanding suggests that FIV transmission through casual household contact (grooming, sharing bowls) is quite rare, and stable households with no aggressive interactions may not require intervention beyond preventing fighting. The decision to vaccinate negative cats living with FIV-positive cats should weigh the actual transmission risk, which is low in harmonious households, against the implications of vaccine-induced positive test results for the vaccinated cats.

Shelters and rescue organizations historically faced difficult decisions about FIV vaccination for cats at risk of exposure in their facilities or after adoption into uncertain situations. The testing implications complicated these decisions, as vaccinated cats would test positive on the antibody tests commonly used in shelter settings, potentially affecting their adoptability and leading to misidentification as infected. Some shelters vaccinated cats going to high-risk situations (outdoor homes, homes with FIV-positive cats), while others avoided vaccination due to testing concerns. Individual shelter policies varied based on their populations, resources, and philosophical approaches to FIV management.

Cats being acquired from unknown backgrounds who will live in situations with potential FIV exposure represent another consideration. New cats whose FIV status is unknown but who will have outdoor access or contact with unknown cats might benefit from vaccination if they test negative for FIV before vaccination. However, the availability of the vaccine and the testing implications must be considered. Some veterinarians recommended testing and vaccinating cats before they entered high-risk situations, while others prioritized keeping cats indoors to prevent exposure rather than vaccinating. Individual risk assessment and detailed discussion with veterinary professionals helps determine the best approach for each situation.

The FIV vaccine protocol involves a series of subcutaneous injections to establish initial immunity, followed by annual boosters for cats with continuing exposure risk. The vaccine is administered under the skin following standard injection technique for feline vaccines, with attention to appropriate injection site selection as recommended for all feline vaccinations. Understanding the complete vaccination protocol is essential for cats to receive full protection, as incomplete series may not provide adequate immunity against this serious viral pathogen.

The initial vaccination series consists of three doses given 2 to 3 weeks apart, beginning in cats 8 weeks of age or older. This multi-dose primary series is necessary to generate robust protective immunity against FIV. All three doses must be completed for the cat to be considered fully vaccinated; cats receiving only one or two doses should not be assumed to have adequate protection. The specific timing between doses should follow manufacturer recommendations, typically 2 to 3 weeks, though slight variations in scheduling are generally acceptable if necessary. Veterinary practices should schedule the complete series at the time of first vaccination to ensure follow-through.

Before initiating FIV vaccination, cats should be tested to confirm they are not already infected with FIV. Vaccinating an FIV-positive cat provides no benefit and wastes resources, while also potentially complicating future health management by obscuring the cat's true infection status with vaccine-induced antibodies on top of infection-induced antibodies. The test must be performed before the first vaccine dose, as vaccine-induced antibodies appear after vaccination and persist long-term. Any cat whose FIV status is unknown must be tested before vaccination is considered. Only cats confirmed negative should receive the vaccine.

Injection site selection follows current guidelines for feline vaccination, which recommend standardized anatomical locations to facilitate monitoring and management of any injection-site reactions. The FIV vaccine, as a non-core vaccine, is typically administered in the left rear leg, below the stifle (knee) joint, as distally as practical. This location allows tracking of which vaccine was given where if reactions develop and facilitates surgical intervention if the rare complication of injection-site sarcoma were to occur. The same general site is used for all doses in the series, though slightly different positions within the designated area help distribute any local tissue reaction.

Annual booster vaccination is recommended for cats with continuing FIV exposure risk. The duration of immunity from FIV vaccination is not definitively established, and annual revaccination maintains protective antibody levels in at-risk cats. Cats whose risk status changes, such as those who become exclusively indoor cats, may discontinue vaccination based on veterinary assessment. The decision to continue annual boosters should be revisited periodically as the cat's circumstances may change over time. Documentation of all FIV vaccinations is essential and should be maintained permanently, as vaccinated cats will test positive on standard FIV antibody tests for the remainder of their lives regardless of continuing vaccination.

Special considerations affect certain patients. Kittens under 8 weeks of age should not be vaccinated due to their immature immune systems. Pregnant cats should ideally be vaccinated before breeding, though the killed nature of the vaccine allows administration during pregnancy if necessary. Immunocompromised cats may have reduced vaccine response. Most importantly, all cats must test FIV-negative before vaccination, and permanent documentation of vaccination must be maintained to prevent future misidentification as infected.

The FIV vaccine's side effect profile includes both typical acute vaccination reactions and a unique long-term consequence that must be understood before vaccination is undertaken. Like other injectable killed vaccines with adjuvants, the FIV vaccine can cause local and systemic reactions representing normal immune responses to vaccination. However, the vaccine's induction of persistent FIV antibodies detectable on standard serological tests represents a permanent consequence that, while not a side effect in the traditional sense, has significant implications for vaccinated cats that must be clearly communicated to cat owners.

Common acute side effects mirror those seen with other killed adjuvanted vaccines. Mild lethargy or decreased activity for 24 to 48 hours following vaccination is common and represents normal immune activation. Some cats experience temporary appetite reduction, low-grade fever, or general malaise. Injection site tenderness or mild swelling occurs in some cats and typically resolves within several days. A small, firm lump may develop at the injection site representing local inflammatory response to vaccine components, particularly the adjuvant. These local reactions usually resolve within 3 to 4 weeks. These reactions, while uncomfortable, are not cause for concern unless they are severe or persistent.

Injection site reactions require ongoing monitoring beyond the acute period. The 3-2-1 rule provides guidance: any lump still present 3 months after injection, larger than 2 centimeters in diameter, or growing 1 month after injection should be evaluated by a veterinarian. Injection-site sarcomas, while rare, have been associated with adjuvanted vaccines in cats. Early detection improves treatment outcomes for these aggressive tumors. Current guidelines recommending distal limb injection sites facilitate both monitoring and surgical intervention if these tumors develop. Cat owners should periodically palpate vaccination sites during the weeks and months following vaccination and report any concerning findings.

Acute allergic reactions, while uncommon, can occur following FIV vaccination as with any vaccine. Signs of allergic response include facial swelling, hives, difficulty breathing, vomiting, diarrhea, or collapse. These reactions require immediate veterinary attention. Cats who experience significant allergic reactions should have these documented in their medical records, and future vaccination decisions should be made carefully. Pre-medication with antihistamines may be considered for cats with previous vaccine reactions who require revaccination, though for a non-core vaccine like FIV, avoiding future vaccination may be preferable if the cat's risk status allows.

The induction of persistent FIV antibodies represents the most significant long-term consequence of FIV vaccination. Vaccinated cats develop antibodies indistinguishable from those produced in response to actual FIV infection on standard point-of-care antibody tests. These antibodies persist for life, meaning vaccinated cats will test positive on routine FIV screening tests indefinitely. This has profound implications: vaccinated cats may be misidentified as infected, potentially affecting their medical care, adoption prospects if they end up in shelters, or their acceptance into new homes. Permanent documentation of vaccination status is essential to prevent these misidentifications, and cat owners must understand this consequence before agreeing to vaccination.

Several important contraindications and considerations apply to FIV vaccination, reflecting both the typical concerns for killed vaccines and unique factors related to the testing implications of this particular vaccine. Understanding these contraindications helps veterinarians identify appropriate vaccination candidates and ensures that cats receive the vaccine only when benefits clearly outweigh potential risks and consequences. The non-core status of this vaccine means that many cats simply do not need it, making careful patient selection particularly important.

Cats already infected with FIV should not receive the vaccine. FIV vaccination provides no therapeutic benefit to infected cats and wastes resources. More importantly, vaccinating an infected cat obscures the relationship between antibody status and infection, potentially complicating future health decisions. All cats must be tested and confirmed FIV-negative before the first vaccine dose is administered. Cats with unknown status who cannot be tested should not be vaccinated until testing can be performed. This requirement is absolute and applies regardless of other factors.

Cats with known hypersensitivity to previous FIV vaccinations or vaccine components should not receive additional doses without careful consideration. Cats who experienced significant allergic reactions, anaphylaxis, or other serious adverse effects following previous vaccination may be at increased risk for similar reactions. Given the non-core status of this vaccine, cats with documented vaccine sensitivities and reduced FIV exposure risk may reasonably discontinue vaccination rather than risk repeated adverse effects. For cats with sensitivity histories who remain at high risk, the veterinarian may recommend pre-medication and extended observation if revaccination is pursued.

Cats at minimal or no risk of FIV exposure should not be vaccinated. The testing implications of vaccination create significant potential for harm if vaccinated cats are later misidentified as infected. Indoor-only cats in single-cat households or in households with only FIV-negative cats face essentially no FIV risk and should not receive this vaccine. Cats whose outdoor access is truly supervised with no opportunity for contact with unknown cats similarly do not benefit from vaccination. Administering this vaccine to cats without genuine exposure risk creates unnecessary testing complications without providing any meaningful protection.

Cats in situations where documentation of vaccination status cannot be reliably maintained may be poor candidates for vaccination. If there is significant concern that vaccination records might be lost, that the cat might be surrendered or rehomed without records, or that future caregivers might not have access to vaccination history, the risk of misidentification as infected may outweigh vaccination benefits. Permanent identification methods such as microchipping can help maintain the connection between the cat and their records, but documentation must still be accessible. This consideration is particularly relevant for rescue organizations and shelters making vaccination decisions for cats with uncertain futures.

Acute illness at the time of scheduled vaccination warrants postponement until the cat has recovered. As with other vaccines, cats with fever, significant infections, or acute health problems should not be vaccinated until their condition stabilizes. Once recovered, vaccination can proceed if FIV testing confirms negative status and exposure risk assessment supports vaccination.

Understanding potential interactions between FIV vaccination and other medications, treatments, and diagnostic tests helps optimize vaccination outcomes and patient care. While the vaccine does not have traditional pharmacological drug interactions with most medications, certain treatments can affect immune response to vaccination. Additionally, the interaction between vaccine-induced antibodies and diagnostic testing represents a crucial consideration that affects how vaccinated cats are managed throughout their lives.

Immunosuppressive medications represent the primary concern regarding vaccine response. Corticosteroids at immunosuppressive doses impair the immune system's ability to generate protective antibodies following vaccination. Cats receiving high-dose prednisone, prednisolone, dexamethasone, or other corticosteroids may have reduced response to FIV vaccination. The three-dose initial series may not produce adequate protective immunity in cats receiving concurrent immunosuppressive therapy. When possible, vaccination should be scheduled during periods of minimal immunosuppression, or timing should be coordinated with the treating veterinarian to optimize immune response.

Other immunosuppressive agents similarly affect vaccine response. Cyclosporine, chemotherapy drugs, and other immunomodulating medications can reduce the immune system's ability to respond to vaccination. Cats undergoing cancer treatment or receiving immunosuppressive therapy for immune-mediated diseases may have suboptimal responses to FIV vaccination. These cats also face complicated medical situations where adding FIV vaccination may not be appropriate. The decision to vaccinate immunocompromised cats should carefully weigh actual exposure risk against the likelihood of achieving protective immunity. For many immunocompromised cats, environmental management to prevent FIV exposure may be more appropriate than vaccination.

The interaction between FIV vaccination and FIV diagnostic testing is the most clinically significant consideration. The vaccine induces antibodies that are detected by standard FIV antibody tests (ELISA, rapid immunochromatographic assays). Vaccinated cats will test positive on these tests for the remainder of their lives, regardless of actual infection status. This creates significant potential for misidentification. Discriminatory PCR tests that can distinguish vaccine-induced antibodies from infection-induced antibodies have been developed but are not universally available and are more expensive than standard antibody testing. When vaccinated cats require FIV testing, veterinarians must know the vaccination history and may need to pursue PCR testing or testing at reference laboratories with appropriate methodology.

Concurrent administration of other vaccines does not create problematic interactions with FIV vaccination. The vaccine can generally be given at the same veterinary visit as FVRCP, rabies, and other vaccines, with each administered at a different anatomical site following standardized guidelines. The FIV vaccine is typically given in the left rear leg, while other vaccines have their own designated sites. While there is no evidence that simultaneous administration reduces vaccine effectiveness, some veterinarians prefer to space vaccines in cats with histories of reactions to allow identification of which vaccine caused any adverse effect.

Appropriate precautions before, during, and after FIV vaccination help ensure optimal outcomes while addressing the unique considerations associated with this vaccine. The testing implications of FIV vaccination require particular attention to documentation and owner education. Understanding these precautions and warnings enables veterinarians and cat owners to make informed decisions about vaccination and to properly manage vaccinated cats throughout their lives.

Pre-vaccination requirements include mandatory FIV testing and thorough owner education about the implications of vaccination. All cats must test negative for FIV antibodies before vaccination can proceed. This testing must occur before the first dose, as vaccine-induced antibodies will interfere with testing afterward. Equally important is ensuring that cat owners fully understand that vaccinated cats will test positive on standard FIV tests for life and that this has significant implications if the cat is ever surrendered, rehomed, lost and found, or tested without knowledge of vaccination history. Owners must commit to maintaining permanent documentation and communicating vaccination status to any future caregivers.

Documentation of FIV vaccination must be comprehensive and permanent. Vaccination records should include the product name, lot number, date of each dose in the series, injection site, and administering veterinarian's information. Owners should receive copies of these records and should store them securely. Vaccination status should be recorded in any microchip registration associated with the cat. Some veterinarians recommend noting FIV vaccination status on the cat's microchip record so that if the cat is found and scanned, the vaccination history can be accessed. This documentation is essential for preventing misidentification of vaccinated cats as infected throughout their lives.

Post-vaccination monitoring follows standard protocols for injectable vaccines. Cats should be observed for 15 to 30 minutes following vaccination to monitor for immediate hypersensitivity reactions. Cat owners should monitor at home for the first 48 to 72 hours, watching for signs exceeding normal mild post-vaccination responses. Injection site monitoring should continue for months following vaccination, with any lumps evaluated according to the 3-2-1 rule. Long-term, owners and veterinarians should be aware of the cat's vaccinated status for all future medical care to ensure appropriate interpretation of any FIV testing that might be performed.

Special populations require additional consideration. Kittens under 8 weeks should not be vaccinated. Pregnant cats can receive killed vaccines if necessary, though vaccination before breeding is preferred. Cats going through significant life changes, such as those being rehomed or placed in shelters, present particular concerns regarding documentation continuity. Geriatric cats may be reassessed for continuing vaccination need if their lifestyle has become more restricted. Throughout all these situations, the permanence of vaccine-induced antibody response and the need for lifelong documentation should guide decision-making.

Owner education about responsible cat ownership alongside vaccination deserves emphasis. While vaccination provides protection for cats at risk, the most effective FIV prevention remains keeping cats indoors or in secure outdoor enclosures where they cannot contact potentially infected cats. Vaccination should be viewed as one component of comprehensive FIV prevention, not a substitute for preventing exposure. Neutering male cats reduces territorial aggression and fighting behavior that facilitates FIV transmission. A comprehensive approach addressing both vaccination when appropriate and behavioral and environmental risk reduction provides the strongest protection.

Proper storage and handling of the FIV vaccine is essential for maintaining vaccine potency and ensuring that vaccinated cats develop protective immunity. As a killed adjuvanted vaccine, proper handling preserves both the viral antigens and the adjuvant that enhances immune response. While cat owners typically do not handle vaccines directly, understanding storage requirements provides confidence that vaccines administered at veterinary facilities have been properly maintained from manufacture through administration.

Temperature control is the most critical aspect of FIV vaccine storage. The vaccine requires refrigeration at 35-45°F (2-7°C) and must be protected from both freezing and excessive heat. While killed vaccines are generally more stable than live vaccines, improper storage can damage antigens and adjuvants, reducing vaccine effectiveness. Freezing can cause irreversible damage to adjuvant emulsions, affecting both the vaccine's immunogenicity and local tolerance. Excessive heat accelerates antigen degradation. Veterinary practices should use pharmaceutical-grade refrigerators with continuous temperature monitoring to ensure consistent proper storage.

Light protection helps preserve vaccine quality over time. The vaccine should remain in its original packaging until immediately before use, as manufacturer packaging is designed to protect contents from light exposure that can degrade vaccine components. During preparation for administration, vaccines should be kept away from direct sunlight and bright artificial light. The interval between removing the vaccine from refrigeration and administration should be minimized. Any vaccine suspected of improper light or temperature exposure should not be used.

Proper handling during preparation and administration ensures both vaccine effectiveness and patient safety. Staff should verify expiration dates before use, as expired vaccines may have reduced potency. Visual inspection can identify obvious problems such as discoloration, precipitation, or foreign particles. The vaccine should be gently mixed before drawing into the syringe to ensure uniform distribution of all components. Proper aseptic technique during preparation and injection prevents contamination. Multi-dose vials, if used, should be handled according to manufacturer guidelines regarding time limits after first entry.

Supply chain considerations affect FIV vaccine availability differently than for more commonly used vaccines. Because FIV is a non-core vaccine with variable demand, veterinary practices may not maintain continuous stock and may order the vaccine when specific patients need it. This ordering pattern requires attention to shipping conditions, particularly during extreme weather when temperature excursions during transit are more likely. Practices should verify cold chain maintenance upon receipt and contact the supplier if there is any concern about temperature exposure during shipping. The three-dose series requirement means that adequate supply must be available to complete the full protocol once begun.

The FIV vaccine is appropriate for cats of all breeds when risk assessment indicates vaccination is warranted. FIV affects cats regardless of breed, and there are no established breed-specific contraindications or required protocol modifications for this vaccine. The decision to vaccinate should be based on exposure risk factors such as outdoor access and potential for contact with infected cats, rather than breed characteristics. However, certain breed-related management practices may influence when vaccination is considered.

Purebred cats in responsible breeding programs typically have low FIV exposure risk due to controlled environments and known health status of breeding animals. Reputable breeders test breeding cats for FIV and maintain closed catteries where exposure to infected cats is prevented. Kittens from such environments enter the world FIV-negative and, if kept in appropriate environments, remain at low risk. For these cats, vaccination is typically unnecessary unless their future circumstances involve significant exposure risk. The testing implications of vaccination would be particularly problematic for breeding cats or cats who might enter breeding programs, as positive test results could affect their value and breeding prospects.

Show cats present variable FIV risk depending on their management and showing style. Cats who attend shows but remain in carriers and have no direct contact with unfamiliar cats face minimal FIV risk from the show environment. However, cats who have any contact with unknown cats, including cats who escape or have unsupervised interactions, have some exposure potential. FIV transmission requires bite wound exposure, making brief, supervised encounters relatively low risk. The decision to vaccinate show cats should consider the specific circumstances rather than show participation alone. The testing implications of vaccination must be weighed against the actual risk.

Breed size variations do not affect FIV vaccination protocols. Vaccine doses are standardized regardless of patient size because immune response depends on vaccine antigen content rather than body mass. Small breeds and large breeds receive identical doses with equivalent expected immune responses. This applies to the FIV vaccine just as it does to other killed injectable vaccines. The three-dose series and annual booster schedule apply uniformly across breeds.

Some purebred cats may have documented family histories of vaccine sensitivities that warrant consideration when any vaccination is planned. These are individual and family-specific variations rather than breed-wide characteristics. Cats from lines with documented vaccine sensitivity should be carefully evaluated before receiving FIV or any other vaccine. The non-core status of the FIV vaccine means that cats with vaccine sensitivities and manageable FIV exposure risk may reasonably forgo this particular vaccine while receiving other more essential vaccinations with appropriate precautions.

Understanding the FIV vaccine's place within feline retroviral disease prevention helps veterinarians and cat owners develop comprehensive protection strategies. FIV vaccination addresses one of two major feline retroviruses, with feline leukemia virus (FeLV) being the other primary concern. These viruses have different transmission patterns, clinical manifestations, and prevention approaches, and vaccination decisions for each should be made independently based on individual risk assessment.

The feline leukemia virus (FeLV) vaccine is another non-core vaccine that addresses a different retroviral threat. Unlike FIV, which spreads primarily through bite wounds, FeLV transmits through prolonged close contact including mutual grooming, shared food and water bowls, and in utero transmission from infected queens to kittens. This difference in transmission means that cats may have high risk for one virus but not the other. The FeLV vaccine does not interfere with FeLV testing in the same way the FIV vaccine affects FIV testing, though the testing dynamics are different for FeLV (antigen versus antibody testing). Decisions about FIV and FeLV vaccination should be made separately based on the specific risk factors for each virus.

Core vaccines (FVRCP and rabies) remain essential regardless of decisions about retroviral vaccines. The FIV vaccine does not replace core vaccinations, and all cats should receive appropriate core vaccines according to established guidelines. For cats receiving FIV vaccination, the injection site protocol (FIV in the left rear leg, rabies in the right rear leg, FVRCP in the right front leg) allows all vaccines to be given at the same visit while maintaining the ability to track any reactions to specific products.

Antiviral medications for FIV-infected cats represent a different therapeutic category from vaccination. While vaccination prevents infection in uninfected cats, no vaccine can help cats already infected with FIV. Various antiviral agents have been investigated for treating FIV infection, with variable results. Zidovudine (AZT) and some other antiretroviral drugs have shown activity against FIV in some studies, though their use in clinical practice remains limited. Infected cats are generally managed supportively, with attention to preventing and treating secondary infections that result from immunodeficiency. Prevention through vaccination or exposure avoidance remains far preferable to attempting to manage established infection.

Comprehensive FIV prevention extends beyond vaccination to include behavioral and environmental management. Keeping cats indoors or in secure outdoor enclosures eliminates exposure to potentially infected cats. Neutering male cats reduces fighting behavior that facilitates transmission. Testing new cats before introduction to households and maintaining stable social groups minimizes transmission opportunities. Vaccination provides an additional layer of protection for cats at genuine risk but does not replace these fundamental prevention measures. A comprehensive approach combining appropriate vaccination with exposure prevention provides the strongest protection against this serious and incurable viral infection.